Celsion plunges 80 percent as liver cancer therapy fails trial

[riky]

Celsion plunges 80 percent as liver cancer therapy fails trial

(Reuters) - Celsion Corp shares plunged by more than 80 percent after a late-stage study of the company's experimental liver cancer treatment ThermoDox failed to meet the main goal of increasing patients' survival without worsening their cancer. The stock fell to a low of $1.41 before recovering slightly to trade at $1.46 on heavy volume on the Nasdaq on Thursday. "I don't believe the data will support (marketing) registration in any of the major markets," Celsion Chief Executive Michael Tardugno said on a conference call. ...

Source: You are not allowed to view links. Register or Login